We have developed ongoing, collaborative relationships with academic institutions that give us unique access to promising early-stage discoveries. This access to groundbreaking science provides a significant strategic advantage in the rapidly-developing field of microRNA-targeting therapeutics.

Our microRNA development platform serves as the foundation for a diversified pipeline. Our therapeutic areas of focus include cancer, pathologic fibrosis, neuro-inflammatory, and cardiovascular diseases.